CJC-1295 vs ipamorelin: which growth-hormone peptide is the right tool for you?

You want your growth hormone doing more for you — deeper sleep, easier recovery, a body that holds muscle and lets go of fat the way it did ten years ago. Search how, and the same two names come back paired every time: CJC-1295 and ipamorelin, run together, most often every night. The pairing is so standard that most people assume the two are versions of the same thing.

They’re not. They’re two different tools that happen to aim at the same target from different sides. One raises the baseline and holds it there for days. The other fires a clean pulse on your body’s own nightly schedule. Knowing which does what is the difference between copying a forum stack and actually understanding what you’d be putting in your body — and, if you’re choosing, which one fits what you’re after.

What each one could actually do for you

Start with the upside, because on the growth-hormone side it’s genuinely good.

CJC-1295 is the baseline-raiser. It’s a re-engineered version of the natural signal your pituitary uses to release growth hormone, rebuilt so a single shot keeps working for days instead of minutes. In the one human trial that exists, a dose lifted growth hormone two to ten times above baseline for the better part of a week, and kept IGF-1 — the long-acting growth signal GH switches on — elevated for nine to eleven days. Dose weekly and the tide barely drops. If what you want is a steady, sustained lift in the hormones behind recovery and body composition, from as few injections as possible, that’s the CJC-1295 pitch — and the hormone data backs the hormone claim.

Ipamorelin is the pulse. Instead of holding the baseline up, it presses your body’s own release button and lets the pituitary put out a sharp burst of growth hormone — the way it does on its own at night. Its whole selling point is how clean that burst is. Older peptides in this family switched GH on but also dragged up cortisol, your main stress hormone, and prolactin — the messy extras nobody wanted. Raun and colleagues named ipamorelin the first selective growth-hormone secretagogue back in 1998 precisely because it skips them. Want the nightly spike sharpened without stirring up the rest of your endocrine system? That’s ipamorelin’s job.

Why so many people run both

Here’s the reason almost nobody picks one and stops. The two aren’t fighting over the same lever — they’re pulling different ones.

Your pituitary has two separate upstream channels for releasing growth hormone: the GHRH pathway CJC-1295 works on, and the ghrelin pathway ipamorelin hits. Press both at once and, in theory, you get more growth hormone than pressing either alone — CJC-1295 sets the tide higher and holds it, ipamorelin sends a clean wave on top. The two look complementary rather than redundant. That’s the whole logic of the stack, and it’s a tidy one.

Read the asterisk before you treat it as settled, though. Complementary-on-paper is a mechanism story, not a proven result. The theory is coherent. Whether it delivers in an actual human body is a separate question — and it’s the one the next two sections are about.

Which is which, at a glance

Put the two side by side and the division of labour gets obvious — one holds the tide up, the other sends the wave.

The half-life row is the one that explains the pairing. Eight days against two hours isn’t a rounding error — it’s two different jobs. One holds a floor under your growth hormone for a week; the other adds a spike that’s gone by lunchtime. Complementary by design.

How far the proof actually goes — for both

Now the boundary, drawn straight for both, because the mechanism story is where these two shine and the human story is where they thin out.

CJC-1295 has exactly one human trial to its name: that 2006 Phase 1. It’s a good one — randomised, placebo-controlled, no serious side effects at the doses tested. But it watched hormones go up, not bodies change. Nobody has run the trial that asks whether raised GH turns into the muscle, sleep or recovery the marketing promises. There’s a second trap hiding in the name, too. CJC-1295 is sold both as the long-acting DAC form the 2006 data actually covers and as a short-acting form — often labelled MOD-GRF 1-29 — with a thirty-minute half-life and a completely different dosing schedule. Same name, different molecule. From a research-chemical site you often can’t tell which you’re holding.

Ipamorelin’s file is shaped differently, and this is the part the clean reputation quietly skips. Ipamorelin went further than CJC-1295 ever did. Helsinn took it into a real Phase 2 trial — 117 patients recovering from bowel surgery, published by Beck and colleagues in 2014. It came back null. Patients on ipamorelin were no better than placebo on the endpoint that mattered — how fast they got back to eating; the numbers leaned the right way but not far enough to rule out chance (p=0.15). Helsinn read it the same way and shut the programme down. The registered trial record carries that history. So the clean half of the stack is the one with the failed efficacy trial in print. The half that looks cleaner is just the one nobody has pushed hard enough to fail yet.

And the stack itself? No human trial exists — none, for any use. The strongest published support for running them together is a 2026 review describing a single mouse study where the combination improved muscle force in animals bred to lose it. A 2026 aging review lands in the plain place for the whole class: the mechanism holds up, the dose isn’t agreed, and there’s no validated way yet to tell whether it’s working in you. Interesting is not proven. The mechanistic case is coherent; the human case hasn’t been made.

Where the regulators landed

Both peptides sit in the same regulatory spot, and it isn’t the one the forums assume.

Neither CJC-1295 nor ipamorelin is on the FDA’s July 2026 pharmacy-compounding docket — confirmed against the April 2026 Federal Register notice, which names seven other peptides across the two-day session — and neither is on the follow-up review scheduled before the end of February 2027. But absence here isn’t an oversight. The FDA already asked the question. Ipamorelin was reviewed in October 2024 and CJC-1295 in December 2024, and the compounding advisory committee voted against adding either to the list of substances pharmacies are cleared to compound. What that review actually decides — and what it doesn’t — is a longer story we walk through here. The short version: the question got asked for both, and for now the answer was no.

Anti-doping is the simpler line, and it’s identical on both. As growth-hormone releasers, CJC-1295 and ipamorelin both sit inside WADA’s prohibited category at all times, in and out of competition. Not named specifically is not a loophole. If you’re tested, treat both as banned and check the current code on the day — these lists move.

So, on evidence, which one?

Choose on human data alone and neither has earned the certainty the stack marketing projects — but the shortfall is a testing gap, not a mechanism failure. Both are still bets. CJC-1295 does exactly what it claims at the hormone level and has never been tested for outcomes. Ipamorelin has the cleaner design and the one efficacy trial that actually ran, which came back not-yet. Pick the first and you’re betting on a mechanism nobody has tested for outcomes. Pick the second and you’re betting on a mechanism whose one real test came back flat. Run both and you’ve doubled the mechanism story without adding a single human result.

That’s no reason to write either off. The biology behind both is genuinely promising — promising enough that the honest move isn’t to crown a winner off a forum thread. It’s to get each one tested and supervised properly and let the results choose.

That version is the one worth waiting for, and it looks nothing like two vials and a screenshotted protocol. It looks like a physician who knows the difference between CJC-1295 with DAC and without, prescribing against a real reason to use it; a US-licensed pharmacy compounding both under real controls; an assay on every batch; and the null ipamorelin trial named out loud instead of left off the page. Wolverine Health is being built to be exactly that, for the day the regulation makes room for it. Leave your email and we’ll tell you the moment the honest version of this pairing is real — failed trial and all.